Quarterly report · Q1
9776.TEDINET S100OYM4
Period2022-04-01 → 2022-06-30
Filed2022-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥4.9bn | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Revenue | ¥19.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥4.6bn | 2021-04-01 → 2021-06-30 | Cons. | Net sales |
| Operating income | ¥132m | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Operating income | ¥292m | 2021-04-01 → 2021-06-30 | Cons. | Operating income |
| Ordinary income | ¥223m | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.6bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥294m | 2021-04-01 → 2021-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥222m | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥191m | 2021-04-01 → 2021-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥78m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.0bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥107m | 2021-04-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥125m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Net income | ¥106m | 2021-04-01 → 2021-06-30 | Cons. | Profit loss |
| Total assets | ¥16.2bn | at 2022-06-30 | Cons. | Assets |
| Total assets | ¥16.1bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥14.7bn | at 2021-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.8bn | at 2022-06-30 | Cons. | Liabilities |
| Total liabilities | ¥5.8bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥10.4bn | at 2022-06-30 | Cons. | Net assets |
| Net assets / equity | ¥10.3bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥9.5bn | at 2021-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥3.6bn | at 2022-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.0bn | at 2022-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥23.35 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥306.16 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥31.31 | 2021-04-01 → 2021-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 62.3% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 63.0% | at 2021-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-06-30 | ¥23m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-06-30 | ¥22m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥846,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-06-30 | ¥15m |
| jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥2.1bn |
| jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥2.1bn |
| jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥200m |
| jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥2.5bn |
| jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥2.5bn |
| jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥78m |
| jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥376m |
| jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥233m |
| jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥143m |
| jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | −¥3m |
| —segment total | revenue | 2022-04-01 → 2022-06-30 | ¥5.0bn |
| —segment total | revenue external | 2022-04-01 → 2022-06-30 | ¥4.9bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥143m |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | ¥275m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-06-30 | ¥5.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-06-30 | ¥4.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥144m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-06-30 | ¥290m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2021-06-30 | ¥19m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2021-06-30 | ¥19m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥351,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2021-06-30 | ¥11m |
| jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥1.9bn |
| jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥1.9bn |
| jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥304m |
| jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥2.6bn |
| jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥2.6bn |
| jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥131m |
| jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥710m |
| jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥170m |
| jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥539m |
| jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥7m |
| —segment total | revenue | 2021-04-01 → 2021-06-30 | ¥5.2bn |
| —segment total | revenue external | 2021-04-01 → 2021-06-30 | ¥4.6bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥539m |
| —segment total | segment profit | 2021-04-01 → 2021-06-30 | ¥442m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-06-30 | ¥5.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-06-30 | ¥4.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥540m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-06-30 | ¥453m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 380
| Item | Context | Value | Unit |
|---|---|---|---|
| Cost of lease revenue noe | Prior1YTDDuration | 11807000 | JPY |
| Cost of lease revenue noe | CurrentYTDDuration | 11689000 | JPY |
| Other noe | Prior1YTDDuration | 2712000 | JPY |
| Other noe | CurrentYTDDuration | 10000 | JPY |
| Non operating expenses | Prior1YTDDuration | 16753000 | JPY |
| Non operating expenses | CurrentYTDDuration | 13730000 | JPY |
| Ordinary income | Prior1YTDDuration | 293581000 | JPY |
| Ordinary income | CurrentYTDDuration | 223408000 | JPY |
| Gain on sales of noncurrent assets ei | Prior1YTDDuration | 42000 | JPY |
| Gain on sales of noncurrent assets ei | CurrentYTDDuration | 14000 | JPY |
| Extraordinary income | Prior1YTDDuration | 42000 | JPY |
| Extraordinary income | CurrentYTDDuration | 14000 | JPY |
| Loss on retirement of noncurrent assets el | Prior1YTDDuration | 696000 | JPY |
| Loss on retirement of noncurrent assets el | CurrentYTDDuration | 1188000 | JPY |
| Impairment loss el | Prior1YTDDuration | 28552000 | JPY |
| Impairment loss el | CurrentYTDDuration | － | JPY |
| Office transfer expenses el | Prior1YTDDuration | 73127000 | JPY |
| Office transfer expenses el | CurrentYTDDuration | － | JPY |
| Extraordinary loss | Prior1YTDDuration | 102376000 | JPY |
| Extraordinary loss | CurrentYTDDuration | 1188000 | JPY |
| Income before income taxes | Prior1YTDDuration | 191247000 | JPY |
| Income before income taxes | CurrentYTDDuration | 222234000 | JPY |
| Income taxes | Prior1YTDDuration | 85143000 | JPY |
| Income taxes | CurrentYTDDuration | 96994000 | JPY |
| Profit loss | Prior1YTDDuration | 106104000 | JPY |
| Profit loss | CurrentYTDDuration | 125239000 | JPY |
| Profit loss attributable to non controlling interests | Prior1YTDDuration | -1054000 | JPY |
| Profit loss attributable to non controlling interests | CurrentYTDDuration | 47120000 | JPY |
| Profit loss attributable to owners of parent | Prior1YTDDuration | 107158000 | JPY |
| Profit loss attributable to owners of parent | CurrentYTDDuration | 78119000 | JPY |
| Profit loss | Prior1YTDDuration | 106104000 | JPY |
| Profit loss | CurrentYTDDuration | 125239000 | JPY |
| Valuation difference on available for sale securities net of tax oci | Prior1YTDDuration | -30108000 | JPY |
| Valuation difference on available for sale securities net of tax oci | CurrentYTDDuration | -4772000 | JPY |
| Other comprehensive income | Prior1YTDDuration | -30108000 | JPY |
| Other comprehensive income | CurrentYTDDuration | -4772000 | JPY |
| Comprehensive income | Prior1YTDDuration | 75995000 | JPY |
| Comprehensive income | CurrentYTDDuration | 120467000 | JPY |
| Comprehensive income attributable to owners of the parent | Prior1YTDDuration | 77050000 | JPY |
| Comprehensive income attributable to owners of the parent | CurrentYTDDuration | 73346000 | JPY |
| Comprehensive income attributable to non controlling interests | Prior1YTDDuration | -1054000 | JPY |
| Comprehensive income attributable to non controlling interests | CurrentYTDDuration | 47120000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E04950-000ClinicalTestingBusinessReportableSegmentsMember | 1879829000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember | 2570114000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E04950-000MedicalDevicesSalesAndMaintenanceBusinessReportableSegmentsMember | 170346000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReportableSegmentsMember | 4620291000 | JPY |
| Revenues from external customers | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 18521000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 4638812000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E04950-000ClinicalTestingBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |